June 15, 2018 10:16 AM EDT
Peer Review

Aim­mune signs Jayson Dal­las on to suc­ceed re­tir­ing CEO; Ed­uar­do Bra­vo leaves TiGenix in fi­nal chap­ter of Take­da buy­out

Amber Tong

→ Ex-Ul­tragenyx com­mer­cial chief Jayson Dal­las is tak­ing the helm at Aim­mune Ther­a­peu­tics $AIMT — the com­pa­ny best …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

Roche’s TIG­IT drug miss­es last shot at sur­vival end­point win in Phase 3 lung can­cer tri­al

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

A service from the Financial Times